Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against alzheimer's disease

Journal of Alzheimer's Disease

Volumn 31, Issue 1, 2012, Pages 151-165

  Qosa, Hisham ^a   Abuznait, Alaa H ^a   Hill, Ronald A ^a   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Alzheimer's disease; amyloid ; caffeine; LRP1; P gp; rifampicin

Indexed keywords

AMYLOID BETA PROTEIN; CAFFEINE; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; RIFAMPICIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; C57BL 6 MOUSE; CLEARANCE; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPOTHESIS; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UPREGULATION; WILD TYPE;

EID: 84863895905     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120319     Document Type: Article

References (53)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2004) State-specific projections through 2025 of Alzheimer disease prevalence. Neurology 62, 1645. (Pubitemid 38608220)
2. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
3. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13. (Pubitemid 44472602)
4. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
5. Pietrzik C, Behl C (2005) Concepts for the treatment of Alzheimer's disease: Molecular mechanisms and clinical application. Int J Exp Pathol 86, 173-185. (Pubitemid 40813913)
6. Lehman EJ, Kulnane LS, Lamb BT (2003) Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging 24, 645-653. (Pubitemid 37288864)
7. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM (2011) Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14, 750-756.
8. Sommer B (2002) Alzheimer's disease and the amyloid cas-cadehypothesis: Ten years on. Curr Opin Pharmacol 2, 87-92.
9. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4, 191-197. (Pubitemid 46562394)
10. Zlokovic BV, Frangione B (2003) Transport-clearance hypothesis for Alzheimer's disease and potential therapeutic implications. In: Aβ Metabolism in Alzheimer's Disease, Saido TC, ed. Landes Bioscience, Georgetown, TX, pp. 114-122.
11. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-beta (1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499. (Pubitemid 32038587)
12. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17, 347-353. (Pubitemid 47537591)
13. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsada-nian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290. (Pubitemid 41567593)
14. Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Stef-fen J, Schumacher T, Bruning T, Plath AS, Alfen F, Schmidt A, Winter F, Rateitschak K, Wree A, Gsponer J, Walker LC, Pahnke J (2011) Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest 121, 3924-3931.
15. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
16. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J (1996) Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 93, 4229-4234.
17. Abuznait AH, Cain C, Ingram D, Burk D, Kaddoumi A (2011) Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: Investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol 63, 1111-1118.
18. Nicolazzo JA, Mehta DC (2010) Transport of drugs across the blood-brain barrier in Alzheimer's disease. Therapeutic Delivery 1, 595-611.
19. Rapposelli S, Digiacomo M, Balsamo A (2009) P-gp transporter and its role in neurodegenerative diseases. Curr Top Med Chem 9, 209-217.
20. Silverberg GD, Messier AA, Miller MC, Machan JT, Maj-mudar SS, Stopa EG, Donahue JE, Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69, 1034-1043.
21. Herz J, Strickland DK (2001) LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 108, 779-784. (Pubitemid 32880284)
22. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R (1997) Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49, 56-61. (Pubitemid 27328682)
23. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
24. Sharom FJ (1997) The P-glycoprotein multidrug transporter: Interactions with membrane lipids, and their modulation of activity. Biochem Soc Trans 25, 1088-1096. (Pubitemid 27416997)
25. Hartz AM, Miller DS, Bauer B (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77, 715-723.
26. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, McDougall A, Gnarpe J, O'DONNell M, Chernesky M (2004) A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 52, 381-387. (Pubitemid 38339518)
27. Chen X, Ghribi O, Geiger JD (2010) Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 20 (Suppl 1), S127-S141.
28. van Gelder BM, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. Eur J Clin Nutr 61, 226-232.
29. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69, 536-545. (Pubitemid 47357260)
30. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 17, 681-697.
31. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9, 377-382. (Pubitemid 35013893)
32. Abuznait AH, Patrick SG, Kaddoumi A (2011) Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity. J Pharm Pharm Sci 14, 236-248.
33. Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, Yamashita T, Uchiyama Y, Rakugi H, Morishita R (2010) Reduction of brain beta-amyloid (Abeta) by flu-vastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J Biol Chem 285, 22091-22102.
34. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23, 8844-8853. (Pubitemid 37210896)
35. Kakee A, Terasaki T, Sugiyama Y (1996) Brain efflux index as a novel methodofanalyzing efflux transportatthe blood-brain barrier. J Pharmacol Exp Ther 277, 1550-1559. (Pubitemid 27167171)
36. Ito S, Ohtsuki S, Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56, 246-252. (Pubitemid 44572534)
37. Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin corrected. Eur J Cancer 27, 1639-1642.
38. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B (2000) Clearance of amyloid beta-peptide from brain: Transport or metabolism? Nat Med 6, 718-719. (Pubitemid 30469391)
39. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70, 1212-1219. (Pubitemid 44435972)
40. Chiang PK, Lam MA, Luo Y (2008) The many faces of amyloid beta in Alzheimer's disease. Curr Mol Med 8, 580-584.
41. Seeman P, Seeman N (2011) Alzheimer's disease: Beta-amyloid plaque formation in human brain. Synapse 65, 1289-1297.
42. Zong J, Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306, 556-562. (Pubitemid 36886154)
43. Bi W, Zhu L, Wang C, Liang Y, Liu J, Shi Q, Tao E (2011) Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res 1395, 12-20.
44. Xu J, Wei C, Xu C, Bennett MC, Zhang G, Li F, Tao E (2007) Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer. Brain Res 1139, 220-225.
45. Wostyn P, Van Dam D, Audenaert K, De Deyn PP (2011) Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease. Int J Alzheimers Dis 2011, 617420.
46. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Pan-chagnula R (2002) Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. Int J Clin Pharmacol Ther 40, 474-481.
47. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941-952. (Pubitemid 44740473)
48. Nannelli A, Rossignolo F, Tolando R, Rossato P, Pellegatti M, Longo V, Gervasi PG (2010) Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem 337, 133-143.
49. Tanaka H, Mizojiri K (1999) Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther 288, 912-918. (Pubitemid 29254126)
50. Blanchard J (1982) Protein binding of caffeine in young and elderly males. J Pharm Sci 71, 1415-1418. (Pubitemid 13209475)
51. Banks WA, Robinson SM, Verma S, Morley JE (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: Impairment in a mouse model of Alzheimer's disease. Neuroscience 121, 487-492. (Pubitemid 37176936)
52. Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM (2003) Apparent lackofMrp1-mediated effluxatthe lumi-nal side ofmouse blood-brain barrier endothelial cells. Pharm Res 20, 904-909. (Pubitemid 36628438)
53. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C (2000) P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 18, 1837-1844. (Pubitemid 30261921)